Argus lowered shares of Gilead Sciences, Inc. (NASDAQ:GILD) from a buy rating to a hold rating in a research report released on Monday morning. Argus currently has $73.77 target price on the biopharmaceutical company’s stock, up from their previous target price of $73.25.
Several other equities research analysts have also recently issued reports on the stock. Mizuho lifted their price objective on shares of Gilead Sciences from $77.00 to $83.00 and gave the company a buy rating in a research report on Wednesday, November 8th. Maxim Group reiterated a hold rating on shares of Gilead Sciences in a research report on Friday, October 27th. BMO Capital Markets reduced their price objective on shares of Gilead Sciences from $89.00 to $83.00 and set an outperform rating on the stock in a research report on Friday, October 27th. J P Morgan Chase & Co set a $85.00 price objective on shares of Gilead Sciences and gave the company a buy rating in a research report on Wednesday, October 25th. Finally, Leerink Swann lifted their price objective on shares of Gilead Sciences from $84.00 to $85.00 and gave the company a market perform rating in a research report on Thursday, October 19th. One analyst has rated the stock with a sell rating, twelve have assigned a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the company. The company has an average rating of Buy and a consensus target price of $84.87.
Gilead Sciences (NASDAQ GILD) traded down $0.92 during trading on Monday, hitting $72.85. 8,735,200 shares of the stock traded hands, compared to its average volume of 9,357,403. The company has a market capitalization of $92,920.00, a PE ratio of 7.70, a P/E/G ratio of -1.24 and a beta of 1.13. The company has a debt-to-equity ratio of 1.10, a quick ratio of 3.56 and a current ratio of 3.68. Gilead Sciences has a 52-week low of $63.76 and a 52-week high of $86.27.
Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.13 by $0.14. The firm had revenue of $6.51 billion for the quarter, compared to analysts’ expectations of $6.40 billion. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. The company’s revenue for the quarter was down 13.2% compared to the same quarter last year. During the same quarter last year, the business posted $2.75 earnings per share. sell-side analysts expect that Gilead Sciences will post 8.53 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Gilead Sciences, Inc. (GILD) Downgraded by Argus to Hold” was originally published by Stock Observer and is the property of of Stock Observer. If you are accessing this report on another domain, it was illegally stolen and republished in violation of international copyright legislation. The correct version of this report can be read at https://www.thestockobserver.com/2017/11/14/gilead-sciences-inc-gild-downgraded-by-argus-to-hold.html.
The company also recently announced a quarterly dividend, which will be paid on Thursday, December 28th. Shareholders of record on Friday, December 15th will be issued a $0.52 dividend. The ex-dividend date of this dividend is Thursday, December 14th. This represents a $2.08 dividend on an annualized basis and a yield of 2.86%. Gilead Sciences’s dividend payout ratio is presently 23.66%.
In other Gilead Sciences news, CFO Robin L. Washington sold 51,820 shares of the business’s stock in a transaction dated Thursday, September 7th. The shares were sold at an average price of $85.00, for a total value of $4,404,700.00. Following the completion of the transaction, the chief financial officer now directly owns 43,352 shares in the company, valued at $3,684,920. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Gregg H. Alton sold 15,000 shares of the business’s stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $74.82, for a total transaction of $1,122,300.00. Following the completion of the transaction, the executive vice president now owns 77,363 shares of the company’s stock, valued at $5,788,299.66. The disclosure for this sale can be found here. Insiders sold 446,819 shares of company stock valued at $36,269,486 over the last quarter. 1.30% of the stock is currently owned by corporate insiders.
Institutional investors and hedge funds have recently bought and sold shares of the company. Seizert Capital Partners LLC increased its holdings in shares of Gilead Sciences by 4.6% during the first quarter. Seizert Capital Partners LLC now owns 632,574 shares of the biopharmaceutical company’s stock valued at $42,964,000 after acquiring an additional 27,547 shares in the last quarter. Investment Centers of America Inc. increased its holdings in shares of Gilead Sciences by 7.2% during the first quarter. Investment Centers of America Inc. now owns 29,064 shares of the biopharmaceutical company’s stock valued at $1,979,000 after acquiring an additional 1,958 shares in the last quarter. Fagan Associates Inc. increased its holdings in shares of Gilead Sciences by 2.6% during the second quarter. Fagan Associates Inc. now owns 33,075 shares of the biopharmaceutical company’s stock valued at $2,341,000 after acquiring an additional 845 shares in the last quarter. Capital Asset Advisory Services LLC acquired a new position in shares of Gilead Sciences during the second quarter valued at about $875,000. Finally, First PREMIER Bank increased its holdings in shares of Gilead Sciences by 9.0% during the second quarter. First PREMIER Bank now owns 21,533 shares of the biopharmaceutical company’s stock valued at $1,524,000 after acquiring an additional 1,787 shares in the last quarter. Hedge funds and other institutional investors own 74.62% of the company’s stock.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.